Publication:
Serotypes in Adult Pneumococcal Pneumonia in Spain in the Era of Conjugate Vaccines

dc.contributor.authorFernández-Delgado, Lucía
dc.contributor.authorCàmara, Jordi
dc.contributor.authorGonzález-Díaz, Aida
dc.contributor.authorGrau, Inmaculada
dc.contributor.authorShoji, Hisashi
dc.contributor.authorTubau, Fe
dc.contributor.authorMartí, Sara
dc.contributor.authorDomínguez, María Ángeles
dc.contributor.authorCarratalà, Jordi
dc.contributor.authorYuste, Jose Enrique
dc.contributor.authorArdanuy, Carmen
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderGovernment of Catalonia (España)
dc.date.accessioned2022-05-09T07:19:15Z
dc.date.available2022-05-09T07:19:15Z
dc.date.issued2021-10-28
dc.description.abstractWe studied changes in serotype distribution and antimicrobial susceptibility in adult pneumococcal pneumonia in Spain (2011-2019). Among 895 pneumococci collected (433 bacteremic [BPP] and 462 non-bacteremic [non-BPP]), serotypes 3 (17%), 19A (10%), 8 (6.7%) and 11A (6.7%) were the most frequent. Serotypes 16F, 19A and 24F were associated with old people (≥65) and serotypes 4, 7F, 8, 12F and 19F to young adults. Serotypes 12F, 24F and 1 were significantly more frequent in BPP and serotypes 11A, 23A and 19F in non-BPP. Amoxicillin resistance was higher in non-BPP (17% vs. 11%) while penicillin non-susceptibility (37% vs. 24%) and macrolide resistance (29% vs. 14%) were higher in older adults. In the period 2017-2019, the vaccine coverages were: 32% (PCV13), 39% (PCV15), 65% (PCV20) and 69% (PPV23). Differences were found in serotype composition and antimicrobial resistance by age and type of infection. The maintenance of serotype 3 as a leading cause of adult pneumococcal pneumonia and the increase in highly invasive (serotype 8) or antimicrobial-resistant (serotype 11A) serotypes is worrisome. Further studies will be required to analyse the impact of the upcoming broader conjugate vaccines.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was supported by grants from the Fondo de Investigaciones Sanitarias de la Seguridad Social [PI (PI14/00627; PI18/00339, and by CIBER de Enfermedades Respiratorias, CIBERES; [CB06/06/0037], run by the Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Financial support was also provided by the European Regional Development Fund/European Social Fund (ERDF/ESF, “Investing in your future”). We thank CERCA Programme/Generalitat de Catalunya for institutional support.es_ES
dc.format.number11es_ES
dc.format.page2245es_ES
dc.format.volume9es_ES
dc.identifier.citationMicroorganisms. 2021 Oct 28;9(11):2245.es_ES
dc.identifier.doi10.3390/microorganisms9112245es_ES
dc.identifier.issn2076-2607es_ES
dc.identifier.journalMicroorganismses_ES
dc.identifier.pubmedID34835371es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14315
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MSC//CB06%2F06%2F0037/ES/Enfermedades respiratorias 37/es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/null/null/Subprograma de proyectos de investigacion en salud (AES 2014). Modalidad proyectos en salud. (2014)/PI14/00627es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/Subprograma Estatal de Generación de Conocimiento/PI18 - Proyectos de investigacion en salud (AES 2018). Modalidad proyectos en salud. (2018)/PI18/00339es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/microorganisms9112245es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectStreptococcus pneumoniaees_ES
dc.subjectAntimicrobial resistancees_ES
dc.subjectPneumococcal conjugate vaccines (PCVs)es_ES
dc.subjectPneumoniaes_ES
dc.subjectSerotypees_ES
dc.titleSerotypes in Adult Pneumococcal Pneumonia in Spain in the Era of Conjugate Vaccineses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication8e36a2c1-2c2c-4d30-90ad-e0d92630c74f
relation.isAuthorOfPublication.latestForDiscovery8e36a2c1-2c2c-4d30-90ad-e0d92630c74f
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublicationc6fbffec-abb4-4f0e-81e0-3b254d5dd85d
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication30293a55-0e53-431f-ae8c-14ab01127be9
relation.isPublisherOfPublication.latestForDiscovery30293a55-0e53-431f-ae8c-14ab01127be9

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
SerotypesInAdultPneumococcal_2021.pdf
Size:
1.23 MB
Format:
Adobe Portable Document Format
Description: